Mesa Laboratories (MLAB) SVP sells 1,151 shares in open-market trade

Rhea-AI Filing Summary

Mesa Laboratories senior vice president of operations Brian David Archbold reported an open-market sale of company stock. On June 16, 2026, he sold 1,151 shares of Mesa Laboratories common stock at an average price of $101.267 per share. After this transaction, he continues to hold 3,710 shares directly.

Insider Trade Summary 10b5-1

Net Seller: 1,151 shares ($116,558)

Net Sell 1 txn

Insider Archbold Brian David

Role SVP Operations

Sold 1,151 shs ($117K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,151	$101.267	$117K

Holdings After Transaction: Common Stock — 3,710 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 1,151 shares Sale price: $101.267 per share Shares remaining: 3,710 shares +1 more

4 metrics

Shares sold 1,151 shares Common Stock sold on June 16, 2026

Sale price $101.267 per share Average price for the open-market sale

Shares remaining 3,710 shares Total common shares directly owned after transaction

Net shares sold 1,151 shares Net-sell direction in transaction summary

Key Terms

open-market sale, Common Stock, Form 4, net-sell

4 terms

open-market sale financial

"transaction_action: "open-market sale" for 1,151 shares of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock" with 1,151 shares sold at $101.267"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 financial

"Mesa Laboratories insider transaction was disclosed on a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

net-sell financial

"transactionSummary shows netBuySellDirection as "net-sell" for the period"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Archbold Brian David

(Last) (First) (Middle)

12100 W. 6TH AVENUE

(Street)

LAKEWOOD COLORADO 80228

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2026		S		1,151	D	$101.267	3,710	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	John Sakys under Power of Attorney by Brian Archbold	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Mesa Laboratories (MLAB) report for Brian David Archbold?

Mesa Laboratories reported that SVP Operations Brian David Archbold sold 1,151 shares of common stock. The open-market sale occurred at an average price of $101.267 per share and was disclosed on a Form 4 insider trading report.

How many Mesa Laboratories (MLAB) shares does Brian David Archbold hold after the Form 4 sale?

Following the reported sale, Brian David Archbold holds 3,710 Mesa Laboratories common shares directly. This remaining position, disclosed in the Form 4, shows he retained a substantial stake after disposing of 1,151 shares in the open-market transaction.

What was the sale price in the Mesa Laboratories (MLAB) insider transaction?

The reported Mesa Laboratories insider transaction was executed at an average price of $101.267 per share. This price applies to the 1,151 common shares sold by senior vice president of operations Brian David Archbold in an open-market sale reported on Form 4.

What does the Form 4 filing reveal about Mesa Laboratories (MLAB) insider trading direction?

The Form 4 filing shows a net-sell direction for Mesa Laboratories. Brian David Archbold completed one open-market sale of 1,151 common shares and no purchases, resulting in net selling activity for this reporting period according to the transaction summary.

Is the Mesa Laboratories (MLAB) insider transaction a direct or indirect holding change?

The Mesa Laboratories insider transaction reflects a change in direct holdings. The Form 4 classifies the 1,151 shares sold by Brian David Archbold as directly owned, and it reports that he continues to directly own 3,710 common shares after the sale.